Page 172 - Haematologica July

G. Grimnes et al.
Cancer-related inflammation. Nature.
2008;454(7203):436-444.
14. Tichelaar YI, Kluin-Nelemans HJ, Meijer K.
Infections and inflammatory diseases as risk factors for venous thrombosis. A sys- tematic review. Thromb Haemost. 2012; 107(5):827-837.
15. Samad F, Ruf W. Inflammation, obesity, and thrombosis. Blood. 2013;122(20):3415-3422.
16. Schmidt M, Horvath-Puho E, Thomsen RW, Smeeth L, Sorensen HT. Acute infec- tions and venous thromboembolism. J
Intern Med. 2012;271(6):608-618.
17. Smeeth L, Cook C, Thomas S, Hall AJ, Hubbard R, Vallance P. Risk of deep vein thrombosis and pulmonary embolism after acute infection in a community setting.
Lancet. 2006;367(9516):1075-1079.
18. Grimnes G, Isaksen T, Tichelaar YIGV, Braekkan SK, Hansen J-B. Acute infection as a trigger for incident venous throm- boembolism: Results from a population- based case-crossover study. Res Pract
Thromb Haemost. 2018;2(1):85-92.
19. Maclure M. The case-crossover design: a method for studying transient effects on the risk of acute events. Am J Epidemiol.
1991;133(2):144-153.
20. Roumen-Klappe EM, den Heijer M, van
Uum SH, van der Ven-Jongekrijg J, van der Graaf F, Wollersheim H. Inflammatory
response in the acute phase of deep vein thrombosis. J Vasc Surg. 2002;35(4):701- 706.
21. Rogers MA, Levine DA, Blumberg N, Flanders SA, Chopra V, Langa KM. Triggers of hospitalization for venous thromboem- bolism. Circulation. 2012;125(17):2092- 2099.
22. Grainge MJ, West J, Card TR. Venous thromboembolism during active disease and remission in inflammatory bowel dis- ease: a cohort study. Lancet. 2010; 375(9715):657-663.
23. Ogdie A, Kay McGill N, Shin DB, et al. Risk of venous thromboembolism in patients with psoriatic arthritis, psoriasis and rheumatoid arthritis: a general population- based cohort study. Eur Heart J. 2017 Apr 20. [Epub ahead of print]
24. Esmon CT, Xu J, Lupu F. Innate immunity and coagulation. J Thromb Haemost. 2011; 9 Suppl 1:182-188.
25. Medzhitov R. Origin and physiological roles of inflammation. Nature. 2008; 454(7203):428-435.
26. Rittirsch D, Flierl MA, Ward PA. Harmful molecular mechanisms in sepsis. Nat Rev Immunol. 2008;8(10):776-787.
27. Esmon CT. The impact of the inflammato- ry response on coagulation. Thromb Res. 2004;114(5-6):321-327.
28. Esmon CT. Molecular circuits in thrombo- sis and inflammation. Thromb Haemost. 2013;109(3):416-420.
29. Papayannopoulos V. Neutrophil extracellu- lar traps in immunity and disease. Nat Rev Immunol. 2018;18(2):134-147.
30. Martinod K, Wagner DD. Thrombosis: tan- gled up in NETs. Blood. 2014;123(18):2768- 2776.
31. Pepys MB, Hirschfield GM. C-reactive pro- tein: a critical update. J Clin Invest. 2003; 111(12):1805-1812.
32. Singh U, Devaraj S, Jialal I. C-reactive pro- tein decreases tissue plasminogen activator activity in human aortic endothelial cells: evidence that C-reactive protein is a proco- agulant. Arterioscler Thromb Vasc Biol. 2005;25(10):2216-2221.
33. Devaraj S, Yun JM, Adamson G, Galvez J, Jialal I. C-reactive protein impairs the endothelial glycocalyx resulting in endothelial dysfunction. Cardiovasc Res. 2009;84(3):479-484.
34. Pasceri V, Willerson JT, Yeh ET. Direct proinflammatory effect of C-reactive pro- tein on human endothelial cells. Circulation. 2000;102(18):2165-2168.
35. Ridker PM. From C-reactive protein to inter- leukin-6 to interleukin-1: moving upstream to identify novel targets for atheroprotec- tion. Circ Res. 2016;118(1): 145-156.
1250
haematologica | 2018; 103(7)